论文部分内容阅读
目的 :评价希罗达联合铂类抗癌药治疗晚期消化道肿瘤的近期疗效和毒副反应。方法 :希罗达 2 5 0 0mg/m2 ·d-1,分 2次口服 ,连续口服 2周 ,停药 1～ 2周 ;顺铂 6 0～ 80mg/m2 ,分 3天静脉滴注 ,对有肝转移和腹盆腔转移者 ,DDP一次性腹腔灌注 (卡铂 30 0mg/m2 ,用法与顺铂相同 ;草酸铂 130mg/m2 一次性静脉滴注 )。 2 1～ 2 8天为一个周期 ,每个患者最少接受 2个周期的化疗。结果 :完全缓解 (CR) 0例 ,部分缓解 (PR) 17例 ,稳定 (SD) 13例 ,进展 (PD) 6例。有效率 (CR +PR)4 7 2 %。 8例肝转移患者 4例取得部分缓解 ,本组主要毒性反应表现为骨髓抑制、消化道反应、口腔粘膜溃疡、手足综合征。结论 :本方案对治疗晚期消化道肿瘤疗效确切 ,尤其是那些复治和有肝转移者 ,且毒性反应可以耐受
Objective: To evaluate the efficacy and toxicity of Xeloda combined with platinum anticancer drugs in the treatment of advanced gastrointestinal tumors. Methods: Xeloda 250 mg / m2 · d-1, orally 2 times, continuous oral administration for 2 weeks, for 1 to 2 weeks; cisplatin 60 ~ 80mg / m2, intravenous infusion of 3 days, Patients with liver metastases and pelvic metastases, DDP one intraperitoneal infusion (carboplatin 30 0mg / m2, the same usage and cisplatin; oxalate 130mg / m2 a one-time intravenous infusion). 2 1 ~ 28 days for a cycle, each patient received at least 2 cycles of chemotherapy. Results: Complete remission (CR) 0 cases, partial remission (PR) 17 cases, stable (SD) 13 cases, progress (PD) 6 cases. Effective (CR + PR) 4 7 2%. 8 patients with liver metastases in 4 patients achieved partial remission, the main toxicity of this group showed myelosuppression, gastrointestinal reactions, oral mucosal ulcers, hand-foot syndrome. Conclusion: The program for the treatment of advanced gastrointestinal cancer curative effect is exact, especially those retreatment and liver metastasis, and the toxicity can be tolerated